BiotechTube

Pegvaliase-Pqpz

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonurias

Conditions

Phenylketonurias

Trial Timeline

May 25, 2022 → Jul 1, 2025

NCT ID
NCT05356377

About Pegvaliase-Pqpz

Pegvaliase-Pqpz is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is completed. This product is registered under clinical trial identifier NCT05356377. Target conditions include Phenylketonurias.

What happened to similar drugs?

0 of 3 similar drugs in Phenylketonurias were approved

Approved (0) Terminated (0) Active (3)
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
🔄sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinBioMarin PharmaceuticalPhase 3
🔄Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05356377Pre-clinicalCompleted

Competing Products

7 competing products in Phenylketonurias

See all competitors
ProductCompanyStageHype Score
SapropterinBioMarin PharmaceuticalPre-clinical
23
PegvaliaseBioMarin PharmaceuticalPre-clinical
23
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
32
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinBioMarin PharmaceuticalPhase 3
37
PalynziqBioMarin PharmaceuticalPre-clinical
30
Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37